MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2014-09-09
Last Posted Date
2014-09-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
716
Registration Number
NCT02233920

Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2014-09-09
Last Posted Date
2014-09-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4222
Registration Number
NCT02233881

Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2014-09-09
Last Posted Date
2014-09-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
526
Registration Number
NCT02233894

Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

Phase 4
Completed
Conditions
Parkinson Disease
Interventions
First Posted Date
2014-09-08
Last Posted Date
2014-09-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
705
Registration Number
NCT02233023

Tolerability and Safety of Duloxetine BID in Healthy Female Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-09-05
Last Posted Date
2014-09-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
32
Registration Number
NCT02232542

Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain

Phase 3
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: Placebo
First Posted Date
2014-09-05
Last Posted Date
2014-09-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
327
Registration Number
NCT02232555

Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Berodual®
First Posted Date
2014-09-05
Last Posted Date
2014-09-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
834
Registration Number
NCT02232594

Efficacy and Safety of Lacidipine in Chronic Stable Angina

Phase 2
Completed
Conditions
Angina Pectoris
Interventions
Drug: Lacidipine, medium dose
Drug: Lacidipine, high dose
Drug: Lacidipine, low dose
Drug: Placebo
First Posted Date
2014-09-05
Last Posted Date
2014-09-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
283
Registration Number
NCT02232607

Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure

Phase 2
Completed
Conditions
HIV Infections
Interventions
Drug: Placebo
First Posted Date
2014-09-05
Last Posted Date
2014-09-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
72
Registration Number
NCT02232581

Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Berodual® Respimat® solution for inhalation
First Posted Date
2014-09-04
Last Posted Date
2014-09-04
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4602
Registration Number
NCT02231372
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy